Ireland

--:--IST

Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide

Subscribe

Registers› Irish medicines ›Glenmark Pharmaceuticals s.r.o.

Medicines register · Ireland

Glenmark Pharmaceuticals s.r.o. — licensed medicines

10 medicines held by Glenmark Pharmaceuticals s.r.o. on the Irish market, from the HPRA register.

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,295 authorised products are in this register. Synced 05 Oct 2026, 03:28 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

Olazax 10 mg tablets EU/1/09/597/003

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax 15 mg tablets EU/1/09/597/004

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax 20 mg tablets EU/1/09/597/005

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax 5 mg tablets EU/1/09/597/001

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax 7.5 mg tablets EU/1/09/597/002

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax Disperzi 10 mg orodispersible tablets EU/1/09/592/003

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax Disperzi 15 mg orodispersible tablets EU/1/09/592/004

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax Disperzi 20 mg orodispersible tablets EU/1/09/592/005

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Olazax Disperzi 5 mg orodispersible tablets EU/1/09/592/001

Olanzapine

Glenmark Pharmaceuticals s.r.o.

—

Ryaltris 25 microgram/actuation + 600 microgram/actuation nasal spray, suspension PA1543/002/001

Mometasone furoate, Olopatadine

Glenmark Pharmaceuticals s.r.o.

Marketed

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 5 October 2026. https://priyalifescience.com/medicines/company/glenmark-pharmaceuticals-s-r-o

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.